Morgan Stanley Relmada Therapeutics, Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 2,168 shares of RLMD stock, worth $1,777. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,168

Previous 17,197 87.39%

Holding current value

$1,777

Previous $8,000 100.0%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$0.26 - $0.47 $3,907 - $7,063	-15,029 Reduced 87.39%	2,168 $0
Q4 2024 Feb 14, 2025	SELL	$0.35 - $3.65 $7,237 - $75,482	-20,680 Reduced 54.6%	17,197 $8,000
Q3 2024 May 14, 2025	SELL	$2.3 - $4.36 $19,087 - $36,183	-8,299 Reduced 17.97%	37,877 $122,000
Q3 2024 Nov 14, 2024	SELL	$2.3 - $4.36 $19,087 - $36,183	-8,299 Reduced 17.97%	37,877 $122,000
Q2 2024 May 14, 2025	BUY	$2.93 - $4.94 $84,908 - $143,156	28,979 Added 168.51%	46,176 $138,000
Q2 2024 Oct 17, 2024	SELL	$2.93 - $4.94 $217,810 - $367,229	-74,338 Reduced 61.68%	46,176 $138,000
Q2 2024 Aug 14, 2024	SELL	$2.93 - $4.94 $217,810 - $367,229	-74,338 Reduced 61.68%	46,176 $138,000
Q1 2024 Oct 17, 2024	BUY	$3.1 - $6.8 $230,447 - $505,498	74,338 Added 160.99%	120,514 $560,000
Q1 2024 Aug 16, 2024	BUY	$3.1 - $6.8 $94,252 - $206,747	30,404 Added 33.74%	120,514 $560,000
Q1 2024 May 15, 2024	BUY	$3.1 - $6.8 $94,252 - $206,747	30,404 Added 33.74%	120,514 $560,000
Q4 2023 Aug 16, 2024	BUY	$2.45 - $4.22 $107,638 - $185,401	43,934 Added 95.14%	90,110 $373,000
Q4 2023 Feb 13, 2024	SELL	$2.45 - $4.22 $81,406 - $140,217	-33,227 Reduced 26.94%	90,110 $373,000
Q3 2023 Nov 15, 2023	SELL	$2.48 - $3.79 $196,912 - $300,926	-79,400 Reduced 39.16%	123,337 $370,000
Q2 2023 Aug 14, 2023	SELL	$2.22 - $3.54 $322,204 - $513,784	-145,137 Reduced 41.72%	202,737 $498,000
Q1 2023 May 15, 2023	SELL	$2.24 - $4.76 $315,537 - $670,517	-140,865 Reduced 28.82%	347,874 $786,000
Q4 2022 Feb 14, 2023	BUY	$2.17 - $35.84 $425,599 - $7.03 Million	196,129 Added 67.03%	488,739 $1.71 Million
Q3 2022 Nov 14, 2022	SELL	$18.3 - $37.02 $414,074 - $837,651	-22,627 Reduced 7.18%	292,610 $10.8 Million
Q2 2022 Oct 27, 2022	BUY	$16.5 - $30.34 $811,338 - $1.49 Million	49,172 Added 18.48%	315,237 $5.99 Million
Q2 2022 Aug 15, 2022	BUY	$16.5 - $30.34 $811,338 - $1.49 Million	49,172 Added 18.48%	315,237 $5.99 Million
Q1 2022 Oct 27, 2022	SELL	$16.72 - $26.99 $822,155 - $1.33 Million	-49,172 Reduced 15.6%	266,065 $7.18 Million
Q1 2022 May 13, 2022	SELL	$16.72 - $26.99 $5.14 Million - $8.29 Million	-307,256 Reduced 53.59%	266,065 $7.18 Million
Q4 2021 Feb 14, 2022	BUY	$16.93 - $26.82 $2.1 Million - $3.33 Million	123,980 Added 27.59%	573,321 $12.9 Million
Q3 2021 Nov 15, 2021	BUY	$21.86 - $34.77 $9.82 Million - $15.6 Million	449,341 New	449,341 $11.8 Million

Others Institutions Holding RLMD

# of Institutions

Shares Held

6.3M

Call Options Held

Put Options Held

View Full List

About RELMADA THERAPEUTICS, INC.

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $23.5M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

More about RLMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account